NETAAL
This asset is not currently listed on any markets available through Pearler. The information on this page may be inaccurate or out of date.
🇦🇺 ASX
👑 Overview
📈 Performance
💵 Cost
🍃 Esg
🤓 Advanced
👨👩👧👦 Community
📈
N/A
Annual Growth
5 years average annual growth
💵
$ 500
Minimum Order
Due to regulatory requirements
🌏
0
Pearlers Invested
Since January 2020
👑 Overview
Key information
🔎 Fund Overview
Netlinkz Limited - Ordinary Fully Paid Deferred
📈 Performance
Price History
N/A
1M
All Time
Graph
Table
Performance graph isn't available yet for this share
Unsure how much or often to invest?
🗓️ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out →💵 Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out →⏱️ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out →💵 Costs
💼
N/A
Management Fee
Included in unit price, not charged by Pearler
💸
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator🤓 Advanced information
Technical Info
👩👩👦 Community Insights
How our community is investing
🌏 Pearlers invested in NETAAL
0
📊 Total Capital Earnings
N/A
🔃 Average investment frequency
N/A
💵 Average investment amount
N/A
⏰ Last time a customer invested in NETAAL
N/A
NETAAL investor breakdown
💵 Income of investors
More than 200k
150k - 200k
100k - 150k
50k - 100k
Less than 50k
👶 Age of investors
18 - 25
26 - 34
35 - 90
🙋 Legal gender of investors
Female
Male
Pearlers who invest in NETAAL also invest in...
Want more shares? Try these...
Neuren Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in the development of new therapies for brain injury, neurodevelopment, and neurodegenerative disorders. The company is headquartered in Melbourne, Victoria. The company went IPO on 2005-02-03. The firm is developing new drug therapies to treat multiple serious neurological disorders that emerge in early childhood and have no or limited approved treatment options. The Company’s product DAYBUE (trofinetide) is used to treat Rett syndrome in adults and pediatric patients two years of age and older. The United States (US) Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have both granted orphan drug designation to the Company for trofinetide in Fragile X syndrome. Its second product NNZ-2591 is in phase II clinical trials in Phelan-McDermid syndrome, Angelman syndrome, Pitt Hopkins syndrome and Prader-Willi syndrome. The firm has granted an exclusive worldwide license to Acadia Pharmaceuticals Inc. for the development and commercialization of NNZ-259 for Rett syndrome and Fragile X syndrome.
🙌 Performance (5Yr p.a)
86.23%
📊 Share price
$13.81 AUD
📦 LOGISTICS
NetLinkz Ltd. provides a flexible, efficient, secure and cost-effective Software-Defined Wide Area Network solution connecting any site to any device, anywhere, on any network with ease. The firm delivers a cloud-based cyber-secure invisible network-as-a-service (NaaS) for enterprise customers. The company is also a global reseller for Starlink satellite Internet services. Its NaaS proposition is user-centric, creating a per-user private network that is available, secure and performance optimized, for authorized users regardless of their location. The company offers a range of products across three categories: Secure Internet, with Netlinkz transforming Starlink technology into a business grade service providing secure Internet and an invisible cloud network; Network Security, which future proofs clients’ business with Netlinkz’s cloud first private work solutions, and Secure CCTV and IoT, with Netlinkz ensuring that all clients’ video feeds and data from their CCTV and IoT systems are transferred, integrity checked and securely stored. Its products include Starlink FIXED, Starlink FREEDOM and Starlink MARITIME.
🙌 Performance (5Yr p.a)
-18.97%
📊 Share price
$0.00 AUD
🤖 TECHNOLOGY